A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms

Biochemical Pharmacology

Volumn 77, Issue 12, 2009, Pages 1787-1794

  Chen, Bin ^a   Su, Bin ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Breast cancer; COX 2 inhibitor; Her2

Indexed keywords

CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NIMESULIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROMES C; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MITOCHONDRIA; RECEPTOR, ERBB-2; SULFONAMIDES;

EID: 67349247803     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.015     Document Type: Article

References (29)

1. American Cancer Society. Cancer facts and figures 2008, Atlanta; 2008.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
3. Hynes N.E. Tyrosine kinase signalling in breast cancer. Breast Cancer Res 2 (2000) 154-157
4. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
5. Neve R.M., Sutterluty H., Pullen N., Lane H.A., Daly J.M., Krek W., et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19 (2000) 1647-1656
6. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., and Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20 (2000) 3210-3223
7. Spencer K.S., Graus-Porta D., Leng J., Hynes N.E., and Klemke R.L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 148 (2000) 385-397
8. Yen L., Benlimame N., Nie Z.R., Xiao D., Wang T., Al Moustafa A.E., et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 13 (2002) 4029-4044
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
10. Piechocki M.P., Yoo G.H., Dibbley S.K., and Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 67 (2007) 6825-6843
11. Gundla R., Kazemi R., Sanam R., Muttineni R., Sarma J.A., Dayam R., et al. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. J Med Chem 51 (2008) 3367-3377
12. Harris R.E., Namboodiri K., Stellman S.D., and Wynder E.L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 24 (1995) 119-120
13. Harris R.E., Namboodiri K.K., and Farrar W.B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7 (1996) 203-205
14. Mazhar D., Ang R., and Waxman J. COX inhibitors and breast cancer. Br J Cancer 94 (2006) 346-350
15. Harris R.E., Chlebowski R.T., Jackson R.D., Frid D.J., Ascenseo J.L., Anderson G., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63 (2003) 6096-6101
16. Harris R.E., Alshafie G.A., bou-Issa H., and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60 (2000) 2101-2103
17. Zhu J., Huang J.W., Tseng P.H., Yang Y.T., Fowble J., Shiau C.W., et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64 (2004) 4309-4318
18. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94 (2002) 585-591
19. Bae S.H., Jung E.S., Park Y.M., Kim B.S., Kim B.K., Kim D.G., et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7 (2001) 1410-1418
20. Li M., Wu X., and Xu X.C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7 (2001) 1010-1016
21. Sanchez-Alcazar J.A., Bradbury D.A., Pang L., and Knox A.J. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 40 (2003) 33-44
22. Nakatsugi S., Ohta T., Kawamori T., Mutoh M., Tanigawa T., Watanabe K., et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo [4, 5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91 (2000) 886-892
23. Shaik M.S., Chatterjee A., and Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res 10 (2004) 1521-1529
24. Su B., Darby M.V., and Brueggemeier R.W. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem 10 (2008) 475-483
25. Shiau C.W., Yang C.C., Kulp S.K., Chen K.F., Chen C.S., Huang J.W., et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65 (2005) 1561-1569
26. Zhang Z., Lapolla S.M., Annis M.G., Truscott M., Roberts G.J., Miao Y., et al. Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax. J Biol Chem 279 (2004) 43920-43928
27. Liu F.T., Goff L.K., Hao J.H., Newland A.C., and Jia L. Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apoptosis 9 (2004) 377-384
28. Su B., Diaz-Cruz E.S., Landini S., and Brueggemeier R.W. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem 49 (2006) 1413-1419
29. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935